Did Pfizer’s Xeljanz® Cause You Harm?
Have you or a loved one suffered after taking the prescription drug Xeljanz® or Xeljanz XR®?
Xeljanz, Olumiant, and Rinvoq are most commonly used to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. Xeljanz was the first to receive FDA approval for RA in 2012 with other indications coming later.
There are growing reports of patients suffering from serious medical harm among patients who were prescribed Xeljanz. Victims have filed lawsuits against Pfizer after Xeljanz caused blood clots (deep vein thrombosis), pulmonary embolism (PE), cardiac events or cancer.
Xeljanz®: Studies Warn of Its Potential Dangers
By 2018, more than 130,000 patients were taking Xeljanz. The FDA lists the following reports of adverse medical effects to Xeljanz between 2013 and 2018:
- Blood clots (deep vein thrombosis): 52
- Pulmonary embolism:79
- Death: 15
By 2019, the FDA specifically studied the link between patients, their dosage and adverse effects. Patients who took 10mg of Xeljanz twice daily reported the following medical events:
- Pulmonary embolism: 19
- Death: 45
Rheumatoid arthritis patients over the age of 50 who were prescribed a 10mg dose twice daily have an increased chance of experiencing life-threatening blood clots in their lungs.
Xeljanz Linked to Clots, Cardiac Events & Cancer
Blood clots in one’s lungs, also called pulmonary embolisms, are serious because of the impact on the heart. Victims may experience cardiac arrest, myocardial infarction, congestive heart failure and other cardiac events. If not treated promptly, these catastrophic injuries related to Xeljanz use can be fatal.
Other Xeljanz users face a different side effect: cancer. Some patients have been diagnosed with lung cancer, colon cancer, breast cancer, prostate cancer, non-Hodgkin’s lymphoma, or skin cancer.
Cory Watson Holds Drug Manufacturers Accountable
The FDA has issued several warnings now about the risks of taking Xeljanz:
- February 2019: Warning that the use of 10 mg twice daily increased the risk of blood clots in the lungs and death for RA patients. A lower dose should be prescribed for RA patients.
- July 2019: The application of a boxed warning on Xeljanz packaging explaining the risks of blood clots in the lungs and death for RA patients taking the 10 mg twice daily, but also potentially for ulcerative colitis (UC) patients.
- February 2021: Warning of the increased risk of cancer and severe heart problems for Xeljanz users.
- September 2021: FDA required the makers of Xeljanz, Olumiant and Rinvoq new and updated warning labels to alert patients of the potential hazards associated with the drugs.
You likely wish you had known more or had been better protected if you or a loved one suffered from any of the health effects of Xeljanz, Olumiant or Rinvoq. Cory Watson Attorneys has decades of experience helping personal injury victims get the compensation they need and deserve.
Call Cory Watson Attorneys at (877) 562-0000 or fill out the form provided here for a 100% FREE case review. Our legal team will discuss your case and determine what type of compensation could be available to you.